As reviewed above, much has been learned over the past 20 years regarding the pathways that KRAS engages and requires during lung tumorigenesis, and specific inhibitors of these downstream ...

Murine Kras-driven lung cancer models have confirmed the key requirements for RAF, PI3K and RAL-GEF in vivo. Co-opted pathways required by oncogenic KRAS in order to sustain lung tumorigenesis ...

Hereditary changes in genes are often the cause of rare diseases. For example, disease-causing gene variants (PVs) in the ...

Dysregulation of tumor suppressor genes such as p53 and Rb can promote OV replication (e.g., Ads, reovirus). The PKR pathway regulates transcription and can induce abortive apoptosis in response to ...

Erasca has streamlined its pipeline, now focusing on a phase 3 trial for Naporafenib targeting NRAS-mutant melanoma. Read ...

The milestone achievement places NMC Royal Hospital DIP among a select group of only 229 hospitals worldwide to earn this ...

According to DelveInsight’s analysis, the growth of the KRAS Inhibitors market is expected to be mainly driven by increasing incidence, a rise in awareness and access to treatment, and robust pipeline ...

Discover Cardiff Oncology's promising results with Onvansertib for RAS-mutated colorectal cancer, potentially leading to ...

Classically, rational drug combinations are designed to target two nodes in the same oncogenic signalling pathway. BRAF and downstream mitogen-activated extracellular signal-regulated kinase (MEK) ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on ...